What were the key takeaways from Fortrea Holdings's earnings call?

What is the market's earnings forecast for Fortrea Holdings next quarter?

What guidance did Fortrea Holdings's management provide for the next earnings period?

What were the key takeaways from Fortrea Holdings’s earnings call?

What factors drove the changes in Fortrea Holdings's revenue and profit?

What is the revenue and EPS growth rate for Fortrea Holdings year over year?

What is Fortrea Holdings's gross profit margin?

What does Fortrea Holdings do and what are its main business segments?

- **Revenue and Margin Expansion**: Q3 revenue of $701.3 million (+3.9% YoY) with improved book-to-bill of 1.13x. Biotech win rates doubled, driving new client pipeline growth.
- **Operational Efficiency**: 33% faster site selection and 5 months early enrollment in key studies, supported by AI tools like Accelerate Risk Radar.
- **Financial Discipline**: $95 million in gross cost savings, $87 million in operating cash flow, and DSO reduction to 33 days. Raised 2025 revenue guidance to $2.7-$2.75 billion.
- **Strategic Focus**: Biotech operating model with bespoke client solutions, FSP pricing discipline, and clinical pharmacology growth through complex studies.

**【CEO Summary Section】**
- **Revenue and EBITDA Growth**: Q3 revenue of $701.3 million, up 3.9% YoY, with adjusted EBITDA of $50.7 million. Book-to-bill ratio improved to 1.13x, and trailing 12-month book-to-bill remained stable at 1.07x.
- **Biotech Win Rates**: Biotech win rates doubled QoQ, with a focus on Phase II and III studies. New client wins included a rare neuromuscular disease Phase II study and a respiratory disease Phase III trial.
- **Operational Excellence**: Net Promoter Scores (NPS) improved, driven by efficiency gains like 33% faster site selection and 5 months early enrollment in an Alzheimer's study.
- **AI and Technology**: Launched tools like Accelerate Risk Radar and Start My Day to enhance workflow efficiency, with early pilots showing 5-10% productivity gains.
- **Financial Strategy**: Completed a $75.7 million note repurchase and maintained a strong cash position of $25 million from a milestone payment.

**【CFO Financial Commentary】**
- **Profitability Metrics**: GAAP net loss of $15.9 million, with adjusted net income of $11.7 million. GAAP EPS of -$0.13 and adjusted EPS of $0.12.
- **Cash Flow Management**: Generated $87 million in operating cash flow and $80 million in free cash flow, reducing DSO to 33 days (down 17 days YoY).
- **Cost Optimization**: Achieved $95 million in gross cost savings (vs. $150 million target), with $53 million net savings contributing to EBITDA. SG&A reduced 21.6% YoY.
- **Guidance Update**: Raised 2025 revenue guidance to $2.7-$2.75 billion and narrowed adjusted EBITDA to $175-$195 million.

**【Q&A Highlights】**
- **Client Mix and Pricing**: Focused on direct fee revenue growth to improve margins, with cautious FSP pricing to avoid unattractive margins. Biotech RFPs up 40% QoQ, with faster decision-making timelines.
- **Operational Leverage**: Emphasized bespoke approaches for biotech clients, leveraging therapeutic expertise and executive engagement. Clinical pharmacology growth driven by complex studies requiring external sites.
- **Future Outlook**: Targeting 2026 growth through disciplined backlog building and cost management, with no structural barriers to achieving industry-standard margins.

Fortrea Holdings Inc. (FTRE) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 revenue up 7.2% YoY to $710.3M, driven by clinical pharmacology and pass-through costs.
- **Cost Savings**: $50M in gross savings (target $150M) with 8% headcount reduction; 2025 net savings of $90-100M expected.
- **New CEO Strategy**: Focus on innovation, customer engagement, and operational excellence to rebuild biotech trust.
- **Financial Health**: Positive Q2 cash flow ($21.8M) with $400M revolver availability; reaffirmed 2025 EBITDA guidance of $170-200M.
- **Risks**: Biotech hesitancy and Phase 1 capacity constraints, but stable cancellations and strong pharma win rates mitigate risks.

**【Management Opening Remarks】**
- Fortrea reported Q2 2025 revenue of $710.3 million, up 7.2% YoY, driven by clinical pharmacology growth and pass-through costs. Adjusted EBITDA was $54.9 million, flat YoY. Backlog stood at $7.5 billion with a trailing 12-month book-to-bill of 1.1x.
- New biotech customers showed hesitancy due to CEO transition, but win rates remained stable for existing pharma and biotech clients. Clinical pharmacology projects delivered ahead of schedule, including a bioequivalence trial completed in 1 year.
- CFO Jill McConnell highlighted $50 million in gross savings (out of $150M target) and reaffirmed 2025 guidance: revenue $2.1-2.7B, EBITDA $170-200M.

**【CEO Commentary】**
- New CEO Anshul Thakral emphasized Fortrea's role as a clinical development partner, focusing on innovation (e.g., AI-powered Risk Radar tool) and operational excellence. He plans to engage customers globally to rebuild trust post-transition.
- Thakral noted the company's strong customer NPS scores and resilient team, positioning Fortrea to capitalize on biotech pipeline growth despite macro challenges.

**【CFO Financial Commentary】**
- GAAP net loss was $374.9M due to a $309M goodwill impairment, but adjusted net income rose to $17.6M (up from $0.2M YoY). Adjusted EPS was $0.19.
- Operating cash flow improved to $21.8M in Q2, with DSO improving to 46 days (down 5 days QoQ). Liquidity remains strong with $400M revolver availability.
- Cost optimization initiatives reduced SG&A by 20.1% YoY, with 8% headcount reduction. 2025 net savings target is $90-100M, split between gross margin ($50M) and SG&A ($40-50M).

**【Q&A Highlights】**
- **Biotech Hesitancy**: New customers delayed decisions due to leadership uncertainty, but cancellations remained stable at historical levels. Existing clients renewed contracts at consistent rates.
- **Phase 1 Business**: Clinical pharmacology capacity constraints forced third-party reliance, but operational excellence maintained project timelines.
- **Pricing Environment**: Competitive but manageable; Fortrea focuses on value beyond cost, winning 50%+ of RFPs in biotech.
- **2026 Outlook**: CFO expects margin expansion from fully realized SG&A savings, though 2026 guidance will depend on macro trends.
- **Liquidity**: Positive cash flow expected in H2, with $50M revolver balance and $80M+ cash on hand.

Fortrea (FTRE)-6 Aug 25-2025 Q2 Earnings call transcript

- **Revenue Resilience**: Q1 revenue of $651M (-1.6% YoY) reflects slower burn rate, but adjusted EBITDA (+11.8% YoY) and EPS mark Fortrea’s first year-over-year growth post-spin.
- **AI-Driven Efficiency**: AI tools like Copilot Chat adopted across 50%+ employees, with AI assisting in protocol reviews, medical writing, and quality assurance to improve productivity.
- **Cost Transformation**: Targeting $90-$100M net SG&A savings in 2025, with IT spend reduction of 33% and DSO improvement to low/mid-40s by year-end.
- **CEO Transition**: Tom Pike stepping down; interim CEO Peter Neupert leads until new CEO is appointed, with board actively advancing search.
- **Biotech Growth**: Pipeline expands despite funding challenges, with Fortrea’s 50-50 biotech/pharma mix targeting 1.2x book-to-bill long-term.


**【CEO Summary Section】**
- Fortrea reaffirmed its 2025 guidance with Q1 revenue of $651.3 million, down 1.6% YoY due to slower backlog burn rate and complex project mix.
- Book-to-bill ratio of 1.02x for Q1 and 1.14x trailing 12 months reflects solid pipeline, with oncology studies accounting for ~50% of Full-Service Outsourcing revenue and burning 20% slower than other therapeutic areas.
- Management emphasized AI adoption to improve efficiency, with Copilot Chat usage growing 50% week-over-week and AI tools being integrated into protocol reviews, medical writing, and quality assurance.
- CEO Tom Pike announced his departure, with Peter Neupert serving as interim CEO while the board completes CEO succession planning.

**【CFO Financial Commentary】**
- Q1 adjusted EBITDA of $30.3 million (+11.8% YoY) and adjusted EPS of $0.02, marking Fortrea’s first year-over-year growth in adjusted EBITDA and EPS since the spin.
- GAAP net loss of $562.9 million due to a $488.8 million goodwill impairment charge, with no impact on Clinical Pharmacology reporting unit.
- SG&A expenses rose 1.4% YoY to $167.5 million, driven by public company costs, but down 3% sequentially (excluding one-time costs).
- Free cash flow was negative $127.1 million due to ERP conversion-related invoicing pause, with DSO increasing to 51 days from 40 days.
- CFO Jill McConnell reaffirmed 2025 guidance: revenue $2.45-$2.55 billion and adjusted EBITDA $170-$200 million, targeting $90-$100 million net SG&A savings.

**【Q&A Main Questions】**
- **Revenue Cadence**: Q1 strength from pass-through revenue (Clinical Pharmacology) unlikely to repeat; guidance assumes flat revenue for the rest of the year. Burn rate expected to remain 8-8.5x due to oncology and biotech project mix.
- **SG&A Optimization**: $40-$50 million net SG&A savings expected in 2025, with benefits materializing in Q3/Q4. IT spend to be reduced by ~33% over 2024-2025.
- **Cash Flow**: DSO expected to improve to low/mid-40s by year-end, with operating cash flow flat to slightly negative for 2025.
- **CEO Transition**: Board advancing CEO search with interim CEO Peter Neupert focused on stabilizing operations and positioning for growth.
- **Biotech Sentiment**: Pipeline growth offset by funding uncertainty; Fortrea’s 50-50 biotech/pharma mix targets 1.2x book-to-bill long-term, though Q2 has higher biotech exposure.


Fortrea (FTRE)-12 May 25-2025 Q1 Earnings call transcript

- **Strong Book-to-Bill but Mixed Results**: Q4 2024 book-to-bill of 1.35 and $7.7 billion backlog contrast with revenue decline (-1.8% YoY) due to pre-spin project challenges.
- **2025 Guidance Downgrade**: Slower-burning pre-spin projects and inherited costs drive 2025 revenue (-1.5% YoY) and EBITDA margin contraction to 6.7-8.0%.
- **Cost-Saving Focus**: Targeting $40-$50 million SG&A savings in 2025, with 80 basis points reduction in margin impact, and further 100 basis points in 2026.
- **AI and Biotech Growth**: Investing in AI tools for operations and expanding biotech pipeline (50% of wins), with novel AI-driven drug safety solutions.
- **Customer Satisfaction**: NPS scores improved, with successful TSA exit and on-time ERP launches.


**【CEO Summary Section】**
- Fortrea delivered a strong book-to-bill ratio of 1.35 in Q4 2024, with a trailing 12-month ratio of 1.29, resulting in a backlog of $7.7 billion.
- Key wins included repeat business in Phase I clinical pharmacology services (CPS), sole-source awards for oncology and gastroenterology studies, and a novel AI tool for drug safety services.
- The company faced challenges with slower-burning pre-spin projects, particularly in oncology, which impacted 2025 financial outlook.
- Emphasized customer satisfaction improvements, with NPS scores significantly enhanced, and successful exit of transition service agreements (TSAs) with former parent.

**【CFO Financial Commentary】**
- Q4 2024 revenue of $697 million (-1.8% YoY) due to lower late-stage clinical service fees, offset by growth in CPS.
- Adjusted EBITDA of $56 million (-4.3% YoY) and full-year 2024 adjusted EBITDA of $202.5 million (7.5% margin), down from 8.6% in 2023.
- 2025 guidance: Revenue $2.45-$2.55 billion, adjusted EBITDA $170-$200 million, driven by slower pre-spin project burn rates and inherited cost structure.
- Cost-saving initiatives target $40-$50 million in SG&A reductions, with plans to optimize IT, facilities, and vendor spend.
- Free cash flow of $237.3 million in 2024, with $0.5 billion liquidity and compliance with debt covenants.

**【Q&A Highlights】**
- **2025 Financial Challenges**: Pre-spin projects with slower burn rates and lower profitability weighed on guidance, while post-spin wins lagged expectations.
- **Cost Structure**: 80 basis points reduction in SG&A as a percentage of revenue in 2025, with further 100 basis points targeted in 2026.
- **Backlog Dynamics**: $7.7 billion backlog largely intact but slower-burning projects (e.g., oncology) reduced 2025 revenue contribution.
- **AI and Growth**: Accelerate AI adoption in operations, with 185 use cases identified, and focus on biotech growth (50% of pipeline).
- **Shareholder Value**: Reviewing opportunities for growth, cost reduction, and returns, with restructuring charges of $21.3 million in Q4.


FTRE

FTRE fundamentals

Earnings Call

You can ask Aime